FDA considers adding a dozen peptides to its bulk drug compounding list RAPS BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # When will the FDA reclassify BPC 157 to Category 1 Octagon AI BPC 157 & TB 500 Blend 10mg 10mg Peptide Tech Dr Jesse Morse explains why BPC 157 will never receive FDA approval despite its potential to accelerate healing and recovery from injuries. >> More